KPTI - Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

2024-05-08 15:38:52 ET

Karyopharm Therapeutics Inc. (KPTI)

Q1 2024 Earnings Conference Call

May 8, 2024 08:00 ET

Company Participants

Elhan Webb - Senior Vice President of Investor Relations

Richard Paulson - President & Chief Executive Officer

Reshma Rangwala - Chief Medical Officer

Sohanya Cheng - Chief Commercial Officer

Michael Mason - Chief Financial Officer

Conference Call Participants

Chris Raymond - Piper Sandler

Maurice Raycroft - Jefferies

Colleen Kusy - Baird

Brian Abrahams - RBC Capital Markets

Ed White - H.C. Wainwright

Jonathan Chang - Leerink Partners

Presentation

Operator

Good morning. My name is Liz [ph] and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Karyopharm Therapeutics First Quarter 2024 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Elhan Webb, Senior Vice President, Investor Relations.

Elhan Webb

Thank you, Liza [ph] and thank you all for joining us on today's conference call to discuss Karyopharm’s first quarter 2024 financial results and recent company progress. We issued a press release this morning, detailing our financial results for the first quarter 2024. This release along with a slide presentation that we will reference during our call today, are available on our website.

For today's call as seen on Slide 2, I'm joined by Richard, Reshma, Sohanya and Mike, who will provide an update on our first quarter results and recent financing transactions that we announced this morning as well. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements, or FLS, for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined on Slide 3. Actual results may differ materially from those indicated by these FLS as a result of various important factors, including those discussed in the Risk Factors section of our most recent Form 10-K which is on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represent our views as of today only. While we may elect to update this FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these FLS as representing our views as of any later date.

I will now turn the call over to Richard. Please turn to Slide 4.

Richard Paulson

Good morning. Thank you, Elhan and thank you all for joining today for Karyopharm's Q1 2024 Earnings Call. As you have seen this morning, we have shared important news from a financial perspective that strengthens our potential to deliver on our innovation and growth strategy. I'll touch more on this in a moment....

For further details see: